Treatment for Triglycerides 405 mg/dL
For a patient with triglycerides of 405 mg/dL, initiate lifestyle modifications immediately (weight loss, dietary fat restriction, alcohol cessation, exercise) and start statin therapy to address cardiovascular risk, with consideration of adding fibrate or niacin therapy after LDL-C is controlled to achieve a non-HDL-C target of less than 130 mg/dL. 1, 2
Risk Stratification and Initial Assessment
At 405 mg/dL, this patient falls into the moderate hypertriglyceridemia category (200-499 mg/dL) 1, 3. This level poses two distinct risks:
- Cardiovascular disease risk (primary concern at this level)
- Pancreatitis risk (becomes critical only when triglycerides exceed 500 mg/dL)
Essential Workup Before Treatment
Obtain a complete fasting lipid profile within 24 hours to calculate:
- LDL cholesterol
- Non-HDL cholesterol (total cholesterol minus HDL cholesterol)
- HDL cholesterol 1
Screen aggressively for secondary causes:
- Uncontrolled diabetes mellitus (most common)
- Excessive alcohol consumption
- Obesity and metabolic syndrome
- Medications: thiazides, beta-blockers, estrogen, corticosteroids, bile acid resins, protease inhibitors, antipsychotics 4, 3
- Hypothyroidism, nephrotic syndrome, chronic kidney disease
Treatment Algorithm
Step 1: Mandatory Lifestyle Interventions (Class I Recommendation)
Dietary modifications 1:
- Reduce saturated fat to <7% of total calories
- Limit cholesterol to <200 mg/day
- Eliminate trans fats to <1% of energy intake
- Reduce simple carbohydrates and refined sugars
Weight management and physical activity 1:
- Target 5-10% weight loss (can reduce triglycerides by ~20%) 5
- 30-60 minutes of moderate aerobic activity daily (minimum 5 days/week)
- Resistance training 2 days per week
Alcohol cessation is mandatory - patients with very high triglycerides should not consume alcohol 1
Step 2: Pharmacologic Therapy
Primary Treatment: Statin Therapy (Class I, Level A)
Statins are first-line therapy because cardiovascular disease risk is the primary clinical concern at this triglyceride level 1, 2. Statins should be initiated regardless of baseline LDL-C level 1.
Target goals:
- LDL-C <100 mg/dL (Class I)
- Further reduction to <70 mg/dL is reasonable (Class IIa) 1
- Non-HDL-C <130 mg/dL (Class I) 1, 6, 1
Secondary Treatment: Triglyceride-Specific Therapy (Class IIa)
After LDL-C is controlled with statins, consider adding triglyceride-lowering agents 1, 6, 2:
Fibrates (fenofibrate or gemfibrozil):
- Reduce triglycerides by 30-50% 3
- Can be useful after LDL-lowering therapy (Class IIa, Level B) 1
- Critical safety warning: When combining fibrates with statins, keep statin doses relatively low due to increased risk of severe myopathy 1
- Gemfibrozil has higher myopathy risk with statins than fenofibrate
Niacin (prescription nicotinic acid):
- Alternative or adjunct to fibrates (Class IIa, Level B) 1, 6
- Do not use dietary supplement niacin - only prescription formulations 1
- Monitor for flushing, hyperglycemia, hyperuricemia
Omega-3 fatty acids:
- High-dose (2-4 g/day) may be reasonable for triglyceride reduction (Class IIb, Level B) 1, 2
- Icosapent ethyl specifically may reduce cardiovascular events in patients with moderate hypertriglyceridemia on background statin therapy 7, 8
Step 3: Monitoring and Adjustment
Reassess fasting lipid panel in 4-6 weeks after initiating therapy to:
- Verify LDL-C and non-HDL-C targets are met
- Assess triglyceride response
- Monitor for adverse effects (liver enzymes, creatine kinase if on combination therapy)
Critical Clinical Caveats
Bile acid sequestrants are relatively contraindicated when triglycerides exceed 200 mg/dL 1
If triglycerides rise to ≥500 mg/dL, the treatment paradigm shifts entirely - fibrate or niacin becomes first-line before LDL-lowering therapy to prevent pancreatitis 1, 2
For hospitalized patients (e.g., with acute coronary syndrome), lipid-lowering medications should be initiated before discharge 1
The evidence base consistently supports this stepwise approach across multiple ACC/AHA guidelines from 2007-2013, with the Endocrine Society 2012 guidelines providing additional support for fibrate use in moderate hypertriglyceridemia 3. Recent research confirms that while triglyceride-lowering is important, the primary focus remains cardiovascular risk reduction through comprehensive lipid management 7, 8.